Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Phase 2 Completed 48 enrolled Revance Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)

Timeline

Start: 2019-12-06
Primary completion: 2020-11-02
Completion: 2020-11-02

Publications

Dover JS, Humphrey SD, Lorenc ZP, Shamban A, Gross TM, Rubio RG, Vitarella D. Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study. Dermatol Surg. 2023 Jan 1;49(1):60-65. doi: 10.1097/DSS.0000000000003637. Epub 2022 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum toxin type A	Protein / enzyme biologic	32 unknown	Intramuscular
Subject	Botulinum toxin type A	Protein / enzyme biologic	40 unknown	Intramuscular
Subject	Botulinum toxin type A	Protein / enzyme biologic	48 unknown	Intramuscular

Indications

No indication recorded.